Search Results - "Shin Ogawa, Luisa"

The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus by Liu, Yuan, Ye, Josephine, Shin Ogawa, Luisa, Inoue, Takayo, Huang, Qin, Chu, John, Bates, Richard C, Ying, Weiwen, Sonderfan, Andrew J, Rao, Patricia E, Zhou, Dan

“…Systemic lupus erythematosus (SLE) is a complex, systemic autoimmune disease with a diverse range of immunological and clinical manifestations. The…”
Get full text

The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells by Nagai, Masazumi, Vo, Nha H., Shin Ogawa, Luisa, Chimmanamada, Dinesh, Inoue, Takayo, Chu, John, Beaudette-Zlatanova, Britte C., Lu, Rongzhen, Blackman, Ronald K., Barsoum, James, Koya, Keizo, Wada, Yumiko

“…Elesclomol is an investigational drug that exerts potent anticancer activity through the elevation of reactive oxygen species (ROS) levels and is currently…”
Get full text

Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy by Ying, Weiwen, Du, Zhenjian, Sun, Lijun, Foley, Kevin P, Proia, David A, Blackman, Ronald K, Zhou, Dan, Inoue, Takayo, Tatsuta, Noriaki, Sang, Jim, Ye, Shuxia, Acquaviva, Jamie, Ogawa, Luisa Shin, Wada, Yumiko, Barsoum, James, Koya, Keizo

“…Targeted inhibition of the molecular chaperone Hsp90 results in the simultaneous blockade of multiple oncogenic signaling pathways and has, thus, emerged as an…”
Get full text

FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism by Acquaviva, Jaime, He, Suqin, Zhang, Chaohua, Jimenez, John-Paul, Nagai, Masazumi, Sang, Jim, Sequeira, Manuel, Smith, Donald L, Ogawa, Luisa Shin, Inoue, Takayo, Tatsuta, Noriaki, Knowles, Margaret A, Bates, Richard C, Proia, David A

“…Activating mutations and/or overexpression of FGFR3 are common in bladder cancer, making FGFR3 an attractive therapeutic target in this disease. In addition,…”
Get full text

Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors by London, Cheryl A, Acquaviva, Jaime, Smith, Donald L, Sequeira, Manuel, Ogawa, Luisa Shin, Gardner, Heather L, Bernabe, Louis Feo, Bear, Misty D, Bechtel, Sandra A, Proia, David A

“…STA-1474, prodrug of the heat shock protein 90 inhibitor (HSP90i) ganetespib, previously demonstrated activity in canine preclinical models of cancer;…”
Get full text

Abstract P246: Discovery and characterization of selective, FGFR1 sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers by Dardenne, Etienne, Padilla, Fernando, Rasmussen, Sara, Yang, Shao Ning, Mentes, Ahmet, Ogawa, Luisa Shin, Trombino, Anthony, Romashko, Darlene, Chevtsova, Maria, Thakur, Shalabh, Buck, Elisabeth, Roberts, Christopher, Lucas, Matthew, Lin, Tai-An

“…Abstract Background: Targeting FGFR genetic alterations using small molecule inhibitors is a validated therapeutic strategy for urothelial carcinoma and…”
Get full text

A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors by Zhou, Dan, Liu, Yuan, Ye, Josephine, Ying, Weiwen, Ogawa, Luisa Shin, Inoue, Takayo, Tatsuta, Noriaki, Wada, Yumiko, Koya, Keizo, Huang, Qin, Bates, Richard C., Sonderfan, Andrew J.

“…In human trials certain heat shock protein 90 (Hsp90) inhibitors, including 17-DMAG and NVP-AUY922, have caused visual disorders indicative of retinal…”
Get full text

Abstract 3415: Preclinical characterization of a brain penetrant RAF inhibitor, BDTX-4933, targeting oncogenic BRAF Class I/II/III and RAS mutations by Han, Yoon-Chi, Ng, Pui-Yee, Ogawa, Luisa Shin, Yang, Shao Ning, Chen, Miao, Ishiyama, Noboru, Lin, Tai-An, Buck, Elizabeth

“…Abstract Mutations in BRAF and RAS are often oncogenic and lead to a constitutively active MAPK pathway that promotes aberrant cell proliferation and tumor…”
Get full text

HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors by Proia, David A, Smith, Donald L, Zhang, Junyi, Jimenez, John-Paul, Sang, Jim, Ogawa, Luisa Shin, Sequeira, Manuel, Acquaviva, Jaime, He, Suqin, Zhang, Chaohua, Khazak, Vladimir, Astsaturov, Igor, Inoue, Takayo, Tatsuta, Noriaki, Osman, Sami, Bates, Richard C, Chimmanamada, Dinesh, Ying, Weiwen

“…The clinical benefits of chemotherapy are commonly offset by insufficient drug exposures, narrow safety margins, and/or systemic toxicities. Over recent…”
Get full text

Abstract 1619: Hsp90 inhibitor drug conjugates (HDCs): Construct design and preliminary evaluation by Ying, Weiwen, Chimmanamada, Dinesh, Zhang, Junyi, Przewloka, Teresa, Jiang, Jun, Lu, Genliang, Osman, Sami, Loch, James, Vutukuri, Dharma, Chen, Shoujun, Stein, Robert, Chu, John, Proia, David, Rao, Pat, Inoue, Takayo, Ogawa, Luisa Shin, Singh, Ritu, Tatsuta, Noriaki

“…Abstract Background: Most cytotoxic agents are often broadly active but non-selective, and have the disadvantage of high toxicity due to collateral damage to…”
Get full text

Potent anti-inflammatory activity of a novel of class Hsp90 inhibitors for multiple sclerosis (51.1) by Zhou, Dan, Liu, Yuan, Ye, Josephine, Ying, Weiwen, Chimmanamada, Dinesh, Shin Ogawa, Luisa, Inoue, Takayo, Rao, Patricia, Wada, Yumiko

“…Abstract Current therapies for multiple sclerosis (MS) generally reduce the frequency, severity and duration of relapses, and may slow disease progression, but…”
Get full text

Abstract 2509: Hsp90-inhibitor drug conjugates (HDC): Novel tumor-selective drug delivery platform with unprecedented anticancer activity by Chimmanamada, Dinesh, Proia, David, Inoue, Takayo, Ogawa, Luisa Shin, He, Suqin, Sequeira, Manuel, Smith, Donald, Jimenez, John-Paul, Zhang, Chaohua, Sang, Jim, Acquaviva, Jaime, Nagai, Masazumi, Liu, Yuan, Ye, Josephine, Zhou, Dan, Sonderfan, Andrew, Singh, Ritu, Tatsuta, Noriaki, Przewloka, Teresa, Jiang, Jun, Zhang, Junyi, Ying, Weiwen

“…Abstract Background: Various strategies have been used to make chemotherapeutic compounds more tumor selective in order to increase their safety and efficacy,…”
Get full text

Associating retinal drug exposure and retention with the ocular toxicity profiles of Hsp90 inhibitors by Zhou, Dan, Teofilovici, Florentina, Liu, Yuan, Ye, Josephine, Ying, Weiwen, Shin Ogawa, Luisa, Inoue, Takayo, Lee, William, Adjiri-Awere, Alfred, Kolodzieyski, Lev, Tatsuta, Noriaki, Wada, Yumiko, Sonderfan, Andrew J

“…Abstract only 3086 Background: In clinical trials certain Hsp90 inhibitors, including AUY922, SNX-5422, and 17-DMAG have caused visual symptoms suggesting…”
Get full text

Abstract C168: Cancer-selective mitochondrial copper transport by elesclomol results in potent single agent efficacy in multiple tumor types by Sang, Jim, Nagai, Masazumi, Zhang, Chaohua, Smith, Donald, Sequeira, Manuel, Ogawa, Luisa Shin, Ye, Josephine, Liu, Yuan, Inoue, Takayo, Zhou, Dan, Koya, Keizo, Wada, Yumiko

“…Abstract Elesclomol is a first-in-class investigational drug that exerts potent anticancer activity through the elevation of reactive oxygen species (ROS)…”
Get full text

Abstract C212: A critical role for the tissue distribution profile in heat shock protein (Hsp) 90 inhibitor-induced ocular toxicity in rats by Zhou, Dan, Liu, Yuan, Ye, Josephine, Ying, Weiwen, Zhang, Shijie, Ogawa, Luisa Shin, Inoue, Takayo, Tatsuta, Noriaki, Wada, Yumiko, Sonderfan, Andrew, Koya, Keizo

“…Abstract In addition to regulating a number of oncogenic client proteins, the Hsp90 molecular chaperone also controls the folding of key signaling molecules…”
Get full text

Abstract B105: Ganetespib, a unique resorcinolic Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile in preclinical models by Ying, Weiwen, Proia, David A., Zhou, Dan, Inoue, Takayo, Tatsuta, Noriaki, Sang, Jim, Ye, Shuxia, Acquaviva, Jaime, Ogawa, Luisa Shin, Wada, Yumiko, Chimmanamada, Dinesh, Zhang, Shijie, Koya, Keizo

“…Abstract Targeted inhibition of the molecular chaperone heat shock protein 90 (Hsp90) results in the simultaneous blockade of multiple oncogenic signaling…”
Get full text

Abstract 2637: Hsp90 inhibitor STA-9090 enhances the activity of standard of care therapies in erlotinib-sensitive and -resistant NSCLC models by Blackman, Ronald K., Chen, John, Chen, Yu, Foley, Kevin P., Inoue, Takayo, Korbut, Tim, Proia, David A., Sang, Jim, Ogawa, Luisa Shin, Smith, Donald, Tatsuta, Noriaki, Ying, Weiwen, Zhang, Chaohua, Zhang, Haili, Koya, Keizo

“…Abstract BACKGROUND: Heat shock protein 90 (Hsp90) is a molecular chaperone that regulates the folding, stability and activity of many kinases and signal…”
Get full text

Abstract C91: Pharmacodynamic analysis of the Hsp90 inhibitor STA-9090 in a lung cancer xenograft model supports an infrequent dosing schedule in the clinic by Foley, Kevin P., Shimamura, Takeshi, Blackman, Ron K., Borgman, Christa L., Inoue, Takayo, Korbut, Tim, Proia, David, Sang, Jim, Ogawa, Luisa Shin, Smith, Don, Tatsuta, Noriaki, Zhang, Chaohua, Zhang, Haili, Ying, Weiwen, Shapiro, Geoffrey I., Barsoum, James

“…Abstract Background: Heat shock protein 90 (Hsp90) is a molecular chaperone that is required for the stability and function of many important signal…”
Get full text

Abstract B199: In vitro and in vivo efficacy of the novel Hsp90 inhibitor STA-9090 and its synergy with paclitaxel by Ying, Weiwen, Blackman, Ronald K., Chimmanamada, Dinesh, Du, Zhenjian, Foley, Kevin P., He, Suqin, Inoue, Takayo, James, David, Kepros, Jane, Korbut, Tim, Ogawa, Luisa Shin, Peng, Cong, Przewloka, Teresa, Proia, David, Sang, Jim, Smith, Donald, Tatsuta, Noriaki, Yang, Chin-Yu, Zhang, Chaohua, Zhang, Haili, Zhang, Shijie, Li, Shaoguang, Barsoum, James

“…Abstract Heat shock protein 90 (Hsp90) is a molecular chaperone that regulates the post-translational folding of its protein substrates (“client proteins”)…”
Get full text